PolyTherics Ltd - News on 27 May 2008

2008
PolyTherics and Alligator Bioscience announces strategic collaboration for optimisation of next generation biopharmaceuticals
Secretary of State John Denham visits PolyTherics
Novel Approach to Drug Insolubility strengthens PolyTherics patent estate
PolyTherics expands Collaboration with Biocompatibles
PolyTherics-Celtic Pharma Collaboration Agreement to explore technologies for improved drug performance
New Consortium announces Significant Grant Funding of Anaemia product programme

2007
Innovative Drug Production Project secures funding from Technology Strategy Board
Imperial Innovations Annual Report - PolyTherics Limited
PolyTherics highlighted by UK Trade & Investment
Antony Godwin from PolyTherics ties the knot
PolyTherics and BioVectra dcl sign Manufacturing and Representation Deal
Innovative Biopharmaceutical Company, PolyTherics, raises over £2 million
TheraPEG ™ technology ideal for drugs for developing countries

2006
TheraPEG ™ technology wins Research Breakthrough Award
NHS at Hammersmith Hospital applauds new PEGylated IFN
PolyTherics nominated Regional Finalist in UK Biotechnology Entrepreneur Awards 2006
PolyTherics PEGylation technology published in Nature
Debbie Allen and Geeta Gupta joins PolyTherics

2005
PolyTherics and Shantha sign biotech deal
BangaloreBio begins
British High Commissioner addresses Indian biotech companies

Previous | Next
Novel Approach to Drug Insolubility strengthens PolyTherics patent estate

London, UK. Polytherics Ltd ("PolyTherics"), a biopharmaceutical spin-out company from Imperial College London and the London School of Pharmacy that specialises in the targeted application of polymers to biopharmaceuticals, today announced the grant of a European patent on the application of polymer complexation technology to improve drug efficacy. The technology represents a novel method of formulating poorly soluble drugs as solid dosage forms while also providing a means of reducing their systemic toxicity.

Many drug candidates in development fail to fulfil their therapeutic potential owing to poor solubility and toxic side effects. Liposomal dosage forms can address some of these problems but such formulations have been limited to a small number of active agents, remain costly and are difficult to handle, requiring specialist preparation and use.

PolyTherics' polymer complexation technology, the subject of this new European patent, provides a much simpler solution - it creates drug-polymer complexes in a controlled fashion, generating drug preparations with demonstrably improved solubility profiles which are therefore far more cost-effective than existing drug formulations.

One successful application of the technology has been for the fungicide Amphotericin B. PolyTherics has teamed up with the Drugs for Neglected Diseases initiative (DNDi) and has licensed an improved solubility formulation of Amphotericin B for the treatment of Leishmaniasis (see below) in India. PolyTherics has retained exclusive rights to develop the drug for anti-fungal indications and intends to pursue this opportunity independently.

PolyTherics is a company focused on improving both existing and novel protein and small molecule-based drugs, to enhance their performance, longevity and delivery. PolyTherics has developed a proprietary technology, TheraPEG ™, for the targeted modification of protein pharmaceuticals to improve product quality and pharmacokinetic properties. The Company already has five partnerships in progress for the development of TheraPEG ™-based products.

Dr Keith Powell, Chief Executive Officer of PolyTherics, said: "We are delighted with the grant of our European patent, which marks an important milestone for PolyTherics. We have already successfully proven this technology by creating an improved solubility formulation for Amphotericin B and we now aim to develop other drug formulations for wider application. Our expanding intellectual property portfolio gives us considerable scope to apply our technologies to both protein and small molecule products and develop drugs with improved efficacy."

About Leishmaniasis

Leishmaniasis is a parasitic skin disease that is transmitted by the bite of the female sandfly. The symptoms of leishmaniasis are skin sores which erupt weeks to months after the person affected has been bitten. Other consequences, which can become manifest anytime from a few months to years after infection, include fever, damage to the spleen and liver, and anaemia.

Leishmaniasis can be transmitted in many tropical and sub-tropical countries, and is found in around 88 countries. Approximately 350 million people live in these areas. The settings in which leishmaniasis is found range from rainforests in Central and South America to deserts in West Asia and the disease has recently been shown to be spreading to North Texas.

Visceral leishmaniasis is a severe form of the disease in which the parasites have migrated to the vital organs. More than 90 per cent of the world's cases of visceral leishmaniasis are in India, Bangladesh, Nepal, Sudan, and Brazil.

Leishmaniasis is present in Iraq and was contracted by a number of the troops involved in the 2003 invasion and subsequent occupation. The soldiers nicknamed the disease the 'Baghdad boil.' It has been reported by Agence France-Presse that more than 650 US soldiers may have experienced the disease between the start of the invasion in March 2003 and late 2004.

---
27 May 2008

Previous | Next